Search

Your search keyword '"ALFREDO ALBERTI"' showing total 176 results

Search Constraints

Start Over You searched for: Author "ALFREDO ALBERTI" Remove constraint Author: "ALFREDO ALBERTI" Topic gastroenterology Remove constraint Topic: gastroenterology
176 results on '"ALFREDO ALBERTI"'

Search Results

1. Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program

2. Insulin promotes HER2 signaling activation during Barrett’s Esophagus carcinogenesis

Catalog

Books, media, physical & digital resources

3. Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy

4. Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure

5. Optimizing patient referral and center capacity in the management of chronic hepatitis C: Lessons from the Italian experience

6. Impact of HBV infection in HCV/HBV coinfected patients treated with DAAs IN Northern Italy

7. THU-166-Treatment of 320 genotype 3 cirrhotic patients with 12 weeks of sofosbuvir/velpatasvir with or without ribavirin: Real life experience from Italy

8. Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis

9. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study

10. Treatment of 320 genotype 3 cirrhotic patients with 12 weeks Sofosbuvir/Velpatasvir with or without ribavirin: real life experience from Italy

11. Efficacy and safety of Elbasvir/Grazoprevir in a large real-life cohort of HCV-infected patients

12. The evolution of the therapeutic strategy in hepatitis C: Features of sofosbuvir and indications

13. In vivomolecular imaging of HER2 expression in a rat model of Barrett's esophagus adenocarcinoma

14. PC.01.9 ESOPHAGEAL MICROBIOTA COMPOSITION ACROSS BARRETT'S ESOPHAGUS-DYSPLASIA-EAC SEQUENCE

15. Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel

16. How far is noninvasive assessment of liver fibrosis from replacing liver biopsy in hepatitis C?

17. Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C

18. The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases

19. Hepatic iron overload is common in chronic hepatitis B and is more severe in patients coinfected with hepatitis D virus

20. Effectiveness and safety of Sofosbuvir/Velpatasvir/Voxilaprevir for retreatment of chronic hepatitis C patients with a previous failure to direct-acting antivirals: a real-life study from the Navigatore Lombardia and Veneto Networks

21. Long-term liver function changes and related risk factors after direct-acting antiviral therapy in HCV-infected cirrhotic patients: results from a prospective web-based regional platform

22. Impact of a sustained virological response on the long-term outcome of hepatitis C

23. OC.14.1 IS THE ADHERENCE TO WCRF/AICR RECOMMENDATIONS INVOLVED IN BARRETT'S ESOPHAGUS ONSET AND ITS PROGRESSION TO EAC? A RETROSPECTIVE ANALYSIS IN A HIGH-RISK POPULATION

24. SAFE biopsy: A validated method for large-scale staging of liver fibrosis in chronic hepatitis C

25. From current status to optimization of HCV treatment: Recommendations from an expert panel

26. Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases

27. Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications

28. Clinical trial: comparison of weekly once versus twice half-dose weekly administration of pegylated interferon alpha 2b in combination with ribavirin for the treatment of HCV-1 positive patients with chronic hepatitis C

29. Hepatic iron, liver steatosis and viral genotypes in patients with chronic hepatitis C

30. Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse

31. Review article: chronic hepatitis C - natural history and cofactors

32. Optimizing PEG-interferon and ribavirin combination therapy for patients infected with HCV-2 or HCV-3: is the puzzle completed?

33. Cost Effectiveness of Peginterferon ??-2a Plus Ribavirin versus Interferon ??-2b Plus Ribavirin as Initial Therapy for Treatment-Naive Chronic Hepatitis C

34. Evolution of HCV treatments with direct acting antivirals between 2014 and 2017 in 8637 HCV patients in a real world setting: A report from the Lombardia Network and Navigator Study Group

35. Effectiveness and safety of DAA treatment for recurrent hepatitis C after liver transplantation: The NAVIGATOR Lombardia-Veneto network

36. Predictive value of ALT levels for histologic findings in chronic hepatitis C: A European collaborative study

38. The pattern of response to interferon alpha (α-IFN) predicts sustained response to a 6-month α-IFN and ribavirin retreatment for chronic hepatitis C

39. Epidemiology of hepatitis C virus infection in seven European Union countries: a critical analysis of the literature

40. THE ROLE OF HEPATITIS C AND B VIRUS INFECTIONS AS RISK FACTORS FOR SEVERE LIVER COMPLICATIONS FOLLOWING ALLOGENEIC BMT: A PROSPECTIVE STUDY BY THE INFECTIOUS DISEASE WORKING PARTY OF THE EUROPEAN BLOOD AND MARROW TRANSPLANTATION GROUP1

41. Chronic hepatitis C: Interferon retreatment of relapsers. A meta-analysis of individual patient data

42. Comparison of thrice weekly vs daily human leucocyte interferon-alpha therapy for chronic hepatitis C

43. OC.07.7 INSULIN-MEDIATED ESOPHAGEAL ADENOCARCINOMA DEVELOPMENT RELATED TO CHRONIC DUODENUM-ESOPHAGEAL REFLUX IN A HYPERINSULINEMIC AND NON-OBESE MURINE MODEL

44. Interferon Alfacon-1

45. Long-term lymphoblastoid interferon-α therapy for non-cirrhotic chronic hepatitis C: an Italian multicentre study on dose and duration of IFNα treatment

46. Triple therapy with first-generation Protease Inhibitors for patients with genotype 1 chronic hepatitis C: Recommendations of the Italian Association for the Study of the Liver (AISF)

47. Prevalence and Natural History of Hepatitis C Infection in Patients Cured of Childhood Leukemia

48. Morbidity and Mortality Due to Liver Disease in Children Undergoing Allogeneic Bone Marrow Transplantation: A 10-Year Prospective Study

49. Efficacy of a second cycle of interferon therapy in patients with chronic hepatitis C

50. The dilemma for patients with chronic hepatitis C: treat now or warehouse?